Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2018 Aug 9;25(1):145–150. doi: 10.1016/j.bbmt.2018.08.002

Table 3.

Risk factors for PTSD among survey respondents1

  Patient (n=691) Caregiver (n=333)
  N PTSD (%) p value N PTSD (%) p value
Patient age at survey        
▓< 60 years 302 14 (4.6) 0.09 142 12 (8.5) 0.24
▓≥ 60 years 389 9 (2.3) 191 10 (5.2)
Patient age at HCT  
▓< 18 years 30 1 (3)   10 20 (6.2) 0.08
▓> 18 years 661 22 (3)   323 2 (20.0)
Patient sex  
▓Female 322 9 (2.8) 0.47 146 9 (6.2) 0.77
▓Male 369 14 (3.8) 187 13 (7.0)
Time since HCT1  
▓≤ 5 years 203 12 (5.9) 0.01 134 12 (9.0) 0.16
▓> 5 years 488 11 (2.3) 199 10 (5.0)
Type of transplant  
▓Auto 230 8 (3.5) 0.98 118 4 (3.4) 0.13
▓Related allo 253 8 (3.2) 106 7 (6.6)
▓Unrelated allo 208 7 (3.4) 109 11 (10.1)
Disease  
▓Acute myeloid leukemia 133 8 (6.0) 0.14 66 5 (7.6) 0.67
▓Chronic myeloid leukemia 112 0 35 3 (8.6)
▓Myelodysplastic syndrome 93 3 (3.2) 47 5 (10.6)
▓Multiple myeloma 109 5 (4.6)   67 4 (6.0)
▓Lymphoma 132 5 (3.8) 72 4 (5.6)
▓All others 112 2 (1.8) 46 1 (2.2)
Graft source  
▓Bone marrow 220 4 (1.8) 0.26 72 5 (6.9) 0.72
▓Peripheral blood stem cells 457 18 (3.9) 252 17 (6.8)
▓Cord blood 14 1 (7.1) 9 0
Conditioning  
▓Myeloablative 594 20 (3.4) 0.89 270 15 (5.6) 0.11
▓Non-myeloablative 97 3 (3.1) 63 7 (11.1)
Acute GVHD (allo only)  
▓0–1 179 4 (2.2) 0.34 75 5 (6.7) 0.5
▓2–4 285 11 (3.9) 139 13 (9.4)
Chronic GVHD1 (allo only)  
▓Never 169 5 (3.0) 0.8 67 9 (13.4) 0.14
▓≤ 5 years ago 92 4 (4.4) 59 5 (8.5)
▓> 5 years ago 200 6(3.0) 89 4 (4.5)
Relapse1  
▓Never 641 23(3.6) 0.4 309 18 (5.8) 0.10
▓≤ 5 years ago 16 0 10 2 (20.0)
▓> 5 years ago 34 0 14 2 (14.3)
Inpatient days2  
▓≤ 35 days 523 20 (3.8) 0.27 274 18 (6.6) 0.77
▓> 35 days 151 3 (2.0) 52 4 (7.7)
1

All factors defined by patient except ‘time since’ factors

2

Divided on 75th percentile